Lundbeck leaps into the Tourette’s pipeline
By taking out Abide Therapeutics, Lundbeck has bought one of very few clinical-stage Tourette’s syndrome candidates.
Pressure on Abbvie's pipeline grows
Abbvie will need more than Skyrizi and upadacitinib to fill a Humira-shaped hole, and there are a few early-stage candidates it reckons could fit the bill.
Novartis and Biogen face spinal muscular atrophy reckoning
The upcoming American Academy of Neurology meeting could provide clues on how the market will shake out.
Eisai and Biogen throw good money after bad
The companies’ decision to start a 1,500-patient Alzheimer’s disease study defies logic.
Scholar thinks Glaxo made a wise move to back Merck
Scholar Rock selects a lead molecule inhibiting TGF-β, an increasingly important oncology mechanism that Glaxosmithkline recently paid €300m to enter.
Off-the-shelf approaches keep cell therapy investors keen
Five months after Allogene’s flotation there are few signs of waning interest in new issues of cell therapy companies, and they all have one thing in common.
Eidos chases Pfizer in amyloidosis
Eidos presses ahead in its David and Goliath battle against Pfizer in amyloidosis, but it could have issues with pivotal trial recruitment.
Vertex and Crispr up the ante in gene therapy chase
The first sickle cell and beta thalassaemia patients have been enrolled into a Crispr/Cas9 trial, heating up a race with Bluebird, Sanofi, Sangamo and Editas.
12 years on, Astra draws a line under Medimmune
The acquisition marked Astrazeneca’s formal embrace of biologicals. Today the Medimmune name was dropped.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.